Loading...
Market
What will Sarepta's Q4 2024 revenue be?
5
Resolution / Starting Odds
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Sarepta's quarterly earnings report available via SEC filings or company press releases
Story
Sarepta's Elevidy Receives Full FDA Approval for DMD Gene Therapy, Stock Target Set at $200
Jun 30, 2024, 02:16 PM
Sarepta Therapeutics ($SRPT) has received full FDA approval for its gene therapy for ambulatory patients with Duchenne muscular dystrophy (DMD) and accelerated approval for non-ambulatory patients, as detailed in Elevidy's FDA label. This approval is expected to drive significant revenue growth for the company in the coming quarters. BMO Capital has set a conservative target price of $200 for Sarepta's stock, citing no meaningful competition in the near future. Despite this positive outlook, some investors are skeptical, noting disappointment within the DMD community regarding the therapy and Peter Mark's decision, as well as concerns about the empty capsid ratio in AAV technologies.
View original story
Similar markets
Less than $150 • 25%
$150 to $175 • 25%
$175 to $200 • 25%
More than $200 • 25%
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Below $166 • 33%
$166 to $213 • 33%
Above $213 • 34%
Less than $10 billion • 25%
$10 billion to $20 billion • 25%
$20 billion to $30 billion • 25%
More than $30 billion • 25%
Stock price up 0-10% • 33%
Stock price up 10-20% • 33%
Stock price up more than 20% • 34%
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
